Climb Bio (NASDAQ:CLYM – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
Climb Bio Price Performance
NASDAQ CLYM opened at $1.32 on Tuesday. Climb Bio has a one year low of $1.20 and a one year high of $11.55. The firm has a 50-day simple moving average of $1.60. The firm has a market cap of $88.74 million, a price-to-earnings ratio of -0.62 and a beta of -0.19.
Analysts Set New Price Targets
CLYM has been the subject of a number of research reports. Leerink Partners assumed coverage on Climb Bio in a research note on Monday, December 2nd. They issued an “outperform” rating and a $10.00 target price for the company. Leerink Partnrs raised Climb Bio to a “strong-buy” rating in a report on Monday, December 2nd.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Stories
- Five stocks we like better than Climb Bio
- Compound Interest and Why It Matters When Investing
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
